Switch theme
Sign up to access all valuation multiples
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
2019
134
LTM Revenue $67.5M
LTM EBITDA -$96.7M
-$58.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Monte Rosa Therapeutics has a last 12-month revenue of $67.5M and a last 12-month EBITDA of -$96.7M.
In the most recent fiscal year, Monte Rosa Therapeutics achieved revenue of $75.6M and an EBITDA of -$73.0M.
Monte Rosa Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Monte Rosa Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $75.6M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$137M | -$73.0M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -97% | XXX | XXX | XXX |
| Net Profit | -$109M | -$135M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -179% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Monte Rosa Therapeutics's stock price is $4.
Monte Rosa Therapeutics has current market cap of $271M, and EV of -$58.2M.
See Monte Rosa Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$58.2M | $271M | XXX | XXX | XXX | XXX | $-1.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Monte Rosa Therapeutics has market cap of $271M and EV of -$58.2M.
Monte Rosa Therapeutics's trades at -0.9x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.
Analysts estimate Monte Rosa Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Monte Rosa Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$58.2M | XXX | XXX | XXX |
| EV/Revenue | -0.8x | XXX | XXX | XXX |
| EV/EBITDA | 0.8x | XXX | XXX | XXX |
| P/E | -3.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMonte Rosa Therapeutics's NTM/LTM revenue growth is -35%
Monte Rosa Therapeutics's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Monte Rosa Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Monte Rosa Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Monte Rosa Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -97% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -132% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 47% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 161% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 207% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Monte Rosa Therapeutics acquired XXX companies to date.
Last acquisition by Monte Rosa Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Monte Rosa Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Monte Rosa Therapeutics founded? | Monte Rosa Therapeutics was founded in 2019. |
| Where is Monte Rosa Therapeutics headquartered? | Monte Rosa Therapeutics is headquartered in United States of America. |
| How many employees does Monte Rosa Therapeutics have? | As of today, Monte Rosa Therapeutics has 134 employees. |
| Who is the CEO of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's CEO is Mr. Markus Warmuth. |
| Is Monte Rosa Therapeutics publicy listed? | Yes, Monte Rosa Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Monte Rosa Therapeutics? | Monte Rosa Therapeutics trades under GLUE ticker. |
| When did Monte Rosa Therapeutics go public? | Monte Rosa Therapeutics went public in 2021. |
| Who are competitors of Monte Rosa Therapeutics? | Similar companies to Monte Rosa Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's current market cap is $271M |
| What is the current revenue of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's last 12-month revenue is $67.5M. |
| What is the current EBITDA of Monte Rosa Therapeutics? | Monte Rosa Therapeutics's last 12-month EBITDA is -$96.7M. |
| What is the current EV/Revenue multiple of Monte Rosa Therapeutics? | Current revenue multiple of Monte Rosa Therapeutics is -0.9x. |
| What is the current EV/EBITDA multiple of Monte Rosa Therapeutics? | Current EBITDA multiple of Monte Rosa Therapeutics is 0.6x. |
| Is Monte Rosa Therapeutics profitable? | Yes, Monte Rosa Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
